dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lehnert, Thomas |
dc.contributor.author | Röver, Christian |
dc.contributor.author | Köpke, Sascha |
dc.contributor.author | Rio Izquierdo, Jordi |
dc.contributor.author | Fittipaldo, Andrea Veronica |
dc.contributor.author | Chard, Declan |
dc.date.accessioned | 2022-09-13T10:45:57Z |
dc.date.available | 2022-09-13T10:45:57Z |
dc.date.issued | 2022-07-01 |
dc.identifier.citation | Lehnert T, Röver C, Köpke S, Rio J, Chard D, Fittipaldo AV, et al. Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol. Syst Rev. 2022 Jul 1;11:134. |
dc.identifier.issn | 2046-4053 |
dc.identifier.uri | https://hdl.handle.net/11351/8182 |
dc.description | Immunoteràpia; Esclerosi múltiple; Resposta al tractament |
dc.description.sponsorship | Open Access funding enabled and organized by Projekt DEAL. Federal Ministry of Education and Research (BMBF), Germany (grant 01KG1804). The funding body had no influence on the design of the protocol. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Systematic Reviews;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Marcadors bioquímics |
dc.subject | Immunitat |
dc.subject.mesh | Multiple Sclerosis, Relapsing-Remitting |
dc.subject.mesh | /therapy |
dc.subject.mesh | Immunologic Factors |
dc.subject.mesh | Biomarkers |
dc.title | Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s13643-022-01997-2 |
dc.subject.decs | esclerosis múltiple recurrente-remitente |
dc.subject.decs | /terapia |
dc.subject.decs | factores inmunitarios |
dc.subject.decs | biomarcadores |
dc.relation.publishversion | https://doi.org/10.1186/s13643-022-01997-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Lehnert T] Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. [Röver C] Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany. [Köpke S] Institute of Nursing Science, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. [Rio J] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Multiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Chard D] Department of Neuroinfammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK. National Institute for Health Research (NIHR), University College London Hospitals (UCLH) Biomedical Research Centre, London, UK. [Fittipaldo AV] Department of Oncology, Istituto Ricerche Farmacologiche “Mario Negri” IRCCS, Milano, Italy |
dc.identifier.pmid | 35778721 |
dc.identifier.wos | 000819782500002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |